FindTrial
Sign In

Immune response after diphtheria and tetanus toxoid booster in patients with adult onset immunodeficiency with anti-interferon gamma autoantibody

Immune response after diphtheria and tetanus toxoid booster in patients with adult onset immunodeficiency with anti-interferon gamma autoantibody

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190422001
Enrollment
36
Registered
2019-04-22
Start date
2019-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interferon gamma autoantibody interferon gamma autoantibody Diphtheria toxoid Tetanus toxoid Immune response

Interventions

dT Vaccine will be given at baseline. Immune response will be evaluate at 4 weeks after vaccination,dT Vaccine will be given at baseline. Immune response will be evaluate at 4 weeks after vaccination
Experimental Drug,Active Comparator Drug
dT in Interferon gamma autoantibody group,dT in normal host

Sponsors

Ratchadapiseksompoch funds
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age > 18 years who diagnosed with interferon gamma autoantibody

Exclusion criteria

Exclusion criteria: HIV positive Pregnancy

Design outcomes

Primary

MeasureTime frame
Immune response to diphtheria and tetanus toxoid 4 weeks after vaccination Geometric mean titer—

Secondary

MeasureTime frame
Safety of vaccine 4 weeks after vaccination Adverse event—

Countries

Thailand

Contacts

Public ContactDissaruj Tovikkai

Clinical fellow, Faculty of Medicine, Chulalongkorn university

boss_tovikkai@hotmail.com66891352894

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026